Suppr超能文献

预先指示的使用与异基因造血细胞移植患者的临终关怀不那么激进有关。

Advance Directive Utilization Is Associated with Less Aggressive End-of-Life Care in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.

机构信息

Department of Medicine, Blood and Marrow Transplantation, Stanford University, Stanford, California.

Quantitative Sciences Unit, Department of Medicine, Stanford University, Stanford, California.

出版信息

Biol Blood Marrow Transplant. 2018 May;24(5):1035-1040. doi: 10.1016/j.bbmt.2018.01.014. Epub 2018 Jan 31.

Abstract

Allogeneic hematopoietic cell transplantation (HCT) is associated with significant morbidity and mortality, making advance care planning (ACP) and management especially important in this patient population. A paucity of data exists on the utilization of ACP among allogeneic HCT recipients and the relationship between ACP and intensity of healthcare utilization in these patients. We performed a retrospective review of patients receiving allogeneic HCT at our institution from 2008 to 2015 who had subsequently died after HCT. Documentation and timing of advance directive (AD) completion were abstracted from the electronic medical record. Outcomes of interest included use of intensive care unit (ICU) level of care at any time point after HCT, within 30 days of death, and within 14 days of death; use of mechanical ventilation at any time after HCT; and location of death. Univariate logistic regression was performed to explore associations between AD completion and each outcome. Of the 1031 patients who received allogeneic HCT during the study period, 422 decedents (41%) were included in the analysis. Forty-four percent had AD documentation prior to death. Most patients (69%) indicated that if terminally ill, they did not wish to be subjected to life-prolonging treatment attempts. Race/ethnicity was significantly associated with AD documentation, with non-Hispanic white patients documenting ADs more frequently (51%) compared with Hispanic (22%) or Asian patients (35%; P = .0007). Patients with ADs were less likely to use the ICU during the transplant course (41% for patients with ADs versus 52% of patients without ADs; P = .03) and also were less likely to receive mechanical ventilation at any point after transplantation (21% versus 37%, P < .001). AD documentation was also associated with decreased ICU use at the end of life; relative to patients without ADs, patients with ADs were more likely to die at home or in hospital as opposed to in the ICU (odds ratio, .44; 95% confidence interval, .27 to .72). ACP remains underused in allogeneic HCT. Adoption of a systematic practice to standardize AD documentation as part of allogeneic HCT planning has the potential to significantly reduce ICU use and mechanical ventilation while improving quality of care at end of life in HCT recipients.

摘要

异基因造血细胞移植(HCT)与显著的发病率和死亡率相关,这使得预先护理计划(ACP)和管理在这类患者中尤为重要。关于异基因 HCT 受者中 ACP 的利用以及 ACP 与这些患者医疗保健利用强度之间的关系,目前数据有限。我们对 2008 年至 2015 年在我院接受异基因 HCT 后死亡的患者进行了回顾性研究。从电子病历中提取预先指示(AD)完成的文件和时间。感兴趣的结果包括在 HCT 后任何时间点、死亡后 30 天内和死亡后 14 天内使用重症监护病房(ICU)级别的护理;在 HCT 后任何时间使用机械通气;以及死亡地点。使用单变量逻辑回归探讨 AD 完成与每个结果之间的关联。在研究期间接受异基因 HCT 的 1031 名患者中,有 422 名死者(41%)纳入分析。44%的患者在死亡前有 AD 记录。大多数患者(69%)表示,如果生命垂危,他们不希望接受延长生命的治疗尝试。种族/民族与 AD 记录显著相关,非西班牙裔白人患者记录 AD 的频率更高(51%),而西班牙裔(22%)或亚裔患者(35%)较低(P = .0007)。有 AD 的患者在移植过程中使用 ICU 的可能性较低(有 AD 的患者为 41%,无 AD 的患者为 52%;P = .03),在移植后任何时间接受机械通气的可能性也较低(有 AD 的患者为 21%,无 AD 的患者为 37%;P < .001)。AD 记录也与生命末期 ICU 使用减少相关;与没有 AD 的患者相比,有 AD 的患者更有可能在家中或医院而不是 ICU 死亡(比值比,.44;95%置信区间,.27 至.72)。在异基因 HCT 中,ACP 的使用仍然不足。采用系统实践将 AD 记录标准化为异基因 HCT 计划的一部分,有可能显著减少 ICU 使用和机械通气,同时提高 HCT 受者生命末期的护理质量。

相似文献

1
Advance Directive Utilization Is Associated with Less Aggressive End-of-Life Care in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant. 2018 May;24(5):1035-1040. doi: 10.1016/j.bbmt.2018.01.014. Epub 2018 Jan 31.
3
Prospective Randomized Study of Advance Directives in Allogeneic Hematopoietic Cell Transplantation Recipients.
Transplant Cell Ther. 2021 Jul;27(7):615.e1-615.e7. doi: 10.1016/j.jtct.2021.03.030. Epub 2021 Apr 6.
4
End-of-Life Care in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
J Palliat Med. 2022 Jan;25(1):97-105. doi: 10.1089/jpm.2021.0093. Epub 2021 Oct 27.
5
Healthcare Utilization is High in Adult Patients Relapsing after Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant. 2019 Aug;25(8):1659-1665. doi: 10.1016/j.bbmt.2019.04.001. Epub 2019 Apr 6.
7
End-of-Life Care Intensity in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: A Population-Level Analysis.
J Clin Oncol. 2018 Oct 20;36(30):3023-3030. doi: 10.1200/JCO.2018.78.0957. Epub 2018 Sep 5.
8
Advance Care Planning and Palliative Care Integration for Patients Undergoing Hematopoietic Stem-Cell Transplantation.
J Oncol Pract. 2017 Sep;13(9):e721-e728. doi: 10.1200/JOP.2016.020321. Epub 2017 Jun 23.
10
Preliminary report of the integration of a palliative care team into an intensive care unit.
Palliat Med. 2010 Mar;24(2):154-65. doi: 10.1177/0269216309346540. Epub 2009 Oct 13.

引用本文的文献

1
Decision Tree Model for Predicting Hospice Palliative Care Use in Terminal Cancer Patients.
J Hosp Palliat Care. 2021 Sep 1;24(3):184-193. doi: 10.14475/jhpc.2021.24.3.184.
2
[Ethics of resuscitation and end of life decisions].
Notf Rett Med. 2021;24(4):720-749. doi: 10.1007/s10049-021-00888-8. Epub 2021 Jun 2.
3
What is known about palliative care in adult patients with allogeneic stem cell transplantation (allo-SCT)?
Ann Hematol. 2021 Jun;100(6):1377-1389. doi: 10.1007/s00277-021-04538-4. Epub 2021 May 6.
4
Goal of a "Good Death" in End-of-Life Care for Patients with Hematologic Malignancies-Are We Close?
Curr Hematol Malig Rep. 2021 Apr;16(2):117-125. doi: 10.1007/s11899-021-00629-1. Epub 2021 Apr 16.
6
Variables that influence the medical decision regarding Advance Directives and their impact on end-of-life care.
Einstein (Sao Paulo). 2019 Oct 10;18:eRW4852. doi: 10.31744/einstein_journal/2020RW4852. eCollection 2020.
7
Associations Among End-of-Life Discussions, Health-Care Utilization, and Costs in Persons With Advanced Cancer: A Systematic Review.
Am J Hosp Palliat Care. 2019 Oct;36(10):913-926. doi: 10.1177/1049909119848148. Epub 2019 May 9.
8
End-of-Life Care Intensity in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: A Population-Level Analysis.
J Clin Oncol. 2018 Oct 20;36(30):3023-3030. doi: 10.1200/JCO.2018.78.0957. Epub 2018 Sep 5.

本文引用的文献

4
Advance Care Planning and Palliative Care Integration for Patients Undergoing Hematopoietic Stem-Cell Transplantation.
J Oncol Pract. 2017 Sep;13(9):e721-e728. doi: 10.1200/JOP.2016.020321. Epub 2017 Jun 23.
5
End-of-Life Care Patterns Associated with Pediatric Palliative Care among Children Who Underwent Hematopoietic Stem Cell Transplant.
Biol Blood Marrow Transplant. 2016 Jun;22(6):1049-1055. doi: 10.1016/j.bbmt.2016.02.012. Epub 2016 Feb 20.
7
Palliative Care in Adolescents and Young Adults With Cancer.
Cancer Control. 2015 Oct;22(4):475-9. doi: 10.1177/107327481502200413.
8
Spanning the canyon between stem cell transplantation and palliative care.
Hematology Am Soc Hematol Educ Program. 2015;2015:484-9. doi: 10.1182/asheducation-2015.1.484.
9
Patient-Reported Barriers to High-Quality, End-of-Life Care: A Multiethnic, Multilingual, Mixed-Methods Study.
J Palliat Med. 2016 Apr;19(4):373-9. doi: 10.1089/jpm.2015.0403. Epub 2015 Nov 17.
10
Intensive Care Utilization for Hematopoietic Cell Transplant Recipients.
Biol Blood Marrow Transplant. 2015 Nov;21(11):2023-7. doi: 10.1016/j.bbmt.2015.07.026. Epub 2015 Jul 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验